{"id":"W4296006125","doi":"10.1016/j.annonc.2022.07.687","title":"559P Neratinib in HER2-mutant, recurrent/metastatic cervical cancer (R/M CC): Updated findings from the phase 2 SUMMIT basket trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Oncology; EMD Serono; Genentech; Eisai Canada; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; G1 Therapeutics; Sociedad Española de Oncología Médica; Silverback Therapeutics; Mersana Therapeutics; Amgen; Deciphera Pharmaceuticals; AstraZeneca; Novocure; Puma Biotechnology; Regeneron Pharmaceuticals; Clovis Oncology; Pfizer; Incyte; F. Hoffmann-La Roche; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Daiichi Sankyo Europe; Gilead Sciences","keywords":"Medicine; Neratinib; Bevacizumab; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Population; Cancer; Gastroenterology; Chemotherapy; Phases of clinical research; Trastuzumab; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002191748,0.0009561158,0.002158394,0.0003013633,0.0002508897,0.001540849,0.0006101304,0.0007070987,0.003474392],"category_scores_gemma":[0.001893737,0.0002751361,0.001831618,0.000564393,0.0003958557,0.001559962,0.0005081769,0.002144487,0.0008696346],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001315896,"about_ca_system_score_gemma":0.001039262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001701838,"about_ca_topic_score_gemma":0.01011885,"domain_scores_codex":[0.9994255,0.0002059981,0.00005194503,0.00009777272,0.0001006847,0.0001180739],"domain_scores_gemma":[0.9995448,0.0001099755,0.0001386592,0.00003752953,0.0000628749,0.0001060359],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2575441,0.002579697,0.01747953,0.007061177,0.01240318,0.0004287358,0.0003605765,0.007131964,0.01796712,0.002583424,0.0674759,0.6069847],"study_design_scores_gemma":[0.5979133,0.09602006,0.09613383,0.002435423,0.02391996,0.003067546,0.0007377017,0.006044728,0.006828676,0.009891631,0.1565618,0.0004453583],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8687825,0.07609989,0.001738547,0.009434934,0.001464324,0.001728187,0.01757388,0.0004233907,0.02275424],"genre_scores_gemma":[0.9393676,0.0309372,0.002318548,0.005717596,0.0005125215,0.0009607094,0.01383691,0.0001432625,0.006205619],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003474392,"threshold_uncertainty_score":0.01162297,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1009105711707432,"score_gpt":0.4716622743300022,"score_spread":0.370751703159259,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}